Brigitte Schlegelberger

Author

Also Known As

B Schlegelberger, B. Schlegelberger, B. Schlegelberger, BRIGITTE SCHLEGELBERGER, Brigitte Schlegelberger, C Haferlach, C. Fonatsch, D. Haase, Gerald Nyakatura, Gudrun Göhring

724

Publications

33.5K

Citations

H-Index

177

Concepts

All Affiliations

Medizinische Hochschule Hannover Christian-Albrechts-Universität zu Kiel Heidelberg University University of Freiburg German Cancer Research Center

About

Brigitte Schlegelberger is an author at Medizinische Hochschule Hannover specializing in medicine, cell biology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	51	115	9.6K
2	Health Sciences	18	23	1.9K
3	Engineering	4	4	206
4	Natural Sciences	4	4	669
5	Public Health	4	4	184

Brigitte Schlegelberger

291

Publications

28.6K

Citations

H-Index

Page 1

	Year	Citations
Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia Richard F. Schlenk, Konstanze Döhner, Jürgen Krauter, New England Journal of Medicine	2008	1.6K
Oncogene-induced senescence as an initial barrier in lymphoma development Melanie Braig, Soyoung Lee, Christoph Loddenkemper, Nature Tumor BiologyLymphoid NeoplasiaOncogenic AgentLymphoma DevelopmentCellular Senescence	2005	1.2K
Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease Stefan Stein, Marion Ott, Stephan Schultze‐Strasser, Nature Medicine Hematological MalignancyAutoimmune DiseaseGranulocyteEvi1 ActivationImmunology	2010	774
TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome Frank G. Rücker, Richard F. Schlenk, Lars Bullinger, Blood	2011	672
Gene Therapy for Wiskott-Aldrich Syndrome—Long-Term Efficacy and Genotoxicity Christian Braun, Kaan Boztuǧ, Anna Paruzynski, Science Translational Medicine	2014	543
The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML Sabine Käyser, Konstanze Döhner, Jürgen Krauter, Blood	2010	479
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q Pierre Fenaux, Aristoteles Giagounidis, Dominik Selleslag, Blood	2011	475
<i>TP53</i> Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression Martin Jädersten, Leonie Saft, Alexander Smith, Journal of Clinical Oncology	2011	457
<i>RUNX1</i>Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group Verena I. Gaidzik, Lars Bullinger, Richard F. Schlenk, Journal of Clinical Oncology	2011	449
Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes Felicitas Thol, Sofia Kade, Carola Schlarmann, Blood	2012	417

Page 1